Plain-English translation of NCT04077307 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called for patients with advanced blood cancers—such as leukemia, lymphoma, myeloma, and related disorders—that have stopped responding to standard treatments. is taken by mouth every other day. The trial will first test whether the medication is safe and well tolerated at different doses, and then test whether it works even better when combined with other standard cancer treatments.
Patients with advanced blood cancers that return or stop responding to standard treatments have very few options left. This medication is being studied to see if it could offer a new way to help people in this difficult situation by targeting cancer cells through a different mechanism than existing drugs.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will take as an oral solution by mouth every other day. The study starts with small doses that are gradually increased to find the safest dose, and later phases may combine the medication with standard chemotherapy drugs. You will have regular visits with the research team for blood tests, heart monitoring, and imaging scans to check how you are responding and to watch for any side effects. The trial is currently recruiting patients, so the exact schedule and duration will be discussed with you if you are eligible.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark
Serbia
Sweden